Serum Fibroblast Growth Factor 21 Levels Are Correlated with the Severity of Diabetic Retinopathy
Yuan Lin
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYe-cheng Xiao
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorHong Zhu
Department of Endocrinology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 323000, China wzmu.net
Search for more papers by this authorQing-yan Xu
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorLei Qi
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYu-bin Wang
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorXiu-juan Li
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorMa-li Zheng
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorRui-sheng Zhong
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYi Zhang
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorXiang-dong Xu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorBo-le Wu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorCorresponding Author
Zhu-mei Xu
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorCorresponding Author
Xiang-hong Lu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorYuan Lin
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYe-cheng Xiao
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorHong Zhu
Department of Endocrinology, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou 323000, China wzmu.net
Search for more papers by this authorQing-yan Xu
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorLei Qi
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYu-bin Wang
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorXiu-juan Li
Department of Ophthalmology, Xiamen Hospital of Traditional Chinese Medicine, Xiamen 361000, China
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorMa-li Zheng
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorRui-sheng Zhong
Department of Ophthalmology, The Third Affiliated Hospital, Fujian Traditional Chinese Medicine University, Xiamen 361000, China fjtcm.edu.cn
Search for more papers by this authorYi Zhang
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorXiang-dong Xu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorBo-le Wu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorCorresponding Author
Zhu-mei Xu
Key Laboratory of Biotechnology Pharmaceutical Engineering, School of Pharmacy, Wenzhou Medical University, Wenzhou 325035, China wzmu.net
Search for more papers by this authorCorresponding Author
Xiang-hong Lu
Department of Ophthalmology, Lishui People’s Hospital, Wenzhou Medical University, Lishui 323000, China wzmu.net
Search for more papers by this authorAbstract
The aim of the study was to assess serum fibroblast growth factor 21 (FGF21) concentrations in Chinese type 2 diabetic patients with and without retinopathy and to assess the association between FGF21 and the severity of retinopathy. 117 diabetic patients were compared with 68 healthy controls. Fasting blood glucose, serum total cholesterol, serum triglycerides, serum insulin, and serum FGF21 levels were estimated. FGF21 concentrations in the patients were significantly higher than those in control. In the patient group there was a significant positive correlation between FGF21, insulin level, and homeostasis model assessment index. Serum FGF21 concentrations in patients with proliferative diabetic retinopathy or nonproliferative diabetic retinopathy were significantly higher than those in patients without diabetic retinopathy. When the presence of diabetes was defined as the final variable in the conditional logistic regression model with the FGF21 concentration as the continuous variable, FGF21 was significantly involved in the model. This study shows that the increase in serum concentration of FGF21 was associated with the severity of diabetic retinopathy and suggests that FGF21 may play a role in the pathogenesis of diabetic retinopathy and its degree.
References
- 1 Morello C. M., Etiology and natural history of diabetic retinopathy: an overview, American Journal of Health-System Pharmacy. (2007) 64, no. 17, S3–S7, 2-s2.0-35348940263, https://doi.org/10.2146/ajhp070330.
- 2 Song M. K., Roufogalis B. D., and Huang T. H. W., Modulation of diabetic retinopathy pathophysiology by natural medicines through PPAR-γ-related pharmacology, British Journal of Pharmacology. (2012) 165, no. 1, 4–19, 2-s2.0-82955173782, https://doi.org/10.1111/j.1476-5381.2011.01411.x.
- 3 Crawford T. N., AlfaroD. V.III, Kerrison J. B., and Jablon E. P., Diabetic retinopathy and angiogenesis, Current Diabetes Reviews. (2009) 5, no. 1, 8–13, 2-s2.0-65549111100, https://doi.org/10.2174/157339909787314149.
- 4 Varma R., Choudhury F., Klein R., Chung J., Torres M., and Azen S. P., Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study, American Journal of Ophthalmology. (2010) 149, no. 5, 752–761.e3, 2-s2.0-77950810564, https://doi.org/10.1016/j.ajo.2009.11.014.
- 5 Harris Nwanyanwu K., Talwar N., Gardner T. W., Wrobel J. S., Herman W. H., and Stein J. D., Predicting development of proliferative diabetic retinopathy, Diabetes Care. (2013) 36, no. 6, 1562–1568, https://doi.org/10.2337/dc12-0790.
- 6 Davidovic S. P., Nikolic S. V., Curic N. J. et al., Changes of serum VEGF concentration after intravitreal injection of Avastin in treatment of diabetic retinopathy, European Journal of Ophthalmology. (2012) 22, no. 5, 792–798, https://doi.org/10.5301/ejo.5000118.
- 7 Gündüz K. and Bakri S. J., Management of proliferative diabetic retinopathy, Comprehensive Ophthalmology Update. (2007) 8, no. 5, 245–256, 2-s2.0-40949105216.
- 8 Abbate M., Cravedi P., Iliev I., Remuzzi G., and Ruggenenti P., Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives, Current Diabetes Reviews. (2011) 7, no. 3, 190–200, 2-s2.0-79959344912, https://doi.org/10.2174/157339911795843168.
- 9 Abhary S., Burdon K. P., Gupta A., Lake S., Selva D., Petrovsky N., and Craig J. E., Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy, Investigative Ophthalmology and Visual Science. (2009) 50, no. 12, 5552–5558, 2-s2.0-73349129376, https://doi.org/10.1167/iovs.09-3694.
- 10 Ruberte J., Ayuso E., Navarro M., Carretero A., Nacher V., Haurigot V., George M., Llombart C., Casellas A., Costa C., Bosch A., and Bosch F., Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease, Journal of Clinical Investigation. (2004) 113, no. 8, 1149–1157, 2-s2.0-11144354304, https://doi.org/10.1172/JCI200419478.
- 11 Praidou A., Papakonstantinou E., Androudi S., Georgiadis N., Karakiulakis G., and Dimitrakos S., Vitreous and serum levels of vascular endothelial growth factor and platelet-derived growth factor and their correlation in patients with non-proliferative diabetic retinopathy and clinically significant macula oedema, Acta Ophthalmologica. (2011) 89, no. 3, 248–254, 2-s2.0-79955015955, https://doi.org/10.1111/j.1755-3768.2009.01661.x.
- 12 Zakareia F. A., Alderees A. A., Al Regaiy K. A., and Alrouq F. A., Correlation of electroretinography b-wave absolute latency, plasma levels of human basic fibroblast growth factor, vascular endothelial growth factor, soluble fatty acid synthase, and adrenomedullin in diabetic retinopathy, Journal of Diabetes and Its Complications. (2010) 24, no. 3, 179–185, 2-s2.0-77953132225, https://doi.org/10.1016/j.jdiacomp.2008.12.007.
- 13 Belov A. A. and Mohammadi M., Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology, Cold Spring Harbor Perspectives in Biology. (2013) 5, no. 6, a015958, https://doi.org/10.1101/cshperspect.a015958.
- 14 Canto C. and Auwerx J., Cell biology. FGF21 takes a fat bite, Science. (2012) 336, no. 6082, 675–676, https://doi.org/10.1126/science.1222646.
- 15 Smith R., Duguay A., Weiszmann J. et al., A novel approach to improve the function of FGF21, BioDrugs. (2013) 27, no. 2, 159–166, https://doi.org/10.1007/s40259-013-0013-x.
- 16 Xiao Y., Xu A., Law L. S. C., Chen C., Li H., Li X., Yang L., Liu S., Zhou Z., and Lam K. S. L., Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes, Journal of Clinical Endocrinology and Metabolism. (2012) 97, no. 1, E54–E58, 2-s2.0-84855498491, https://doi.org/10.1210/jc.2011-1930.
- 17 Kharitonenkov A., Shiyanova T. L., Koester A., Ford A. M., Micanovic R., Galbreath E. J., Sandusky G. E., Hammond L. J., Moyers J. S., Owens R. A., Gromada J., Brozinick J. T., Hawkins E. D., Wroblewski V. J., Li D.-S., Mehrbod F., Jaskunas S. R., and Shanafelt A. B., FGF-21 as a novel metabolic regulator, Journal of Clinical Investigation. (2005) 115, no. 6, 1627–1635, 2-s2.0-20444435873, https://doi.org/10.1172/JCI23606.
- 18 Lin Z., Gong Q., Wu C. et al., Dynamic change of serum FGF21 levels in response to glucose challenge in human, The Journal of Clinical Endocrinology and Metabolism. (2012) 97, no. 7, E1224–E1228.
- 19 Pyörälä M., Miettinen H., Halonen P., Laakso M., and Pyörälä K., Insulin resistance syndrome predicts the risk of coronary heart disease and stroke in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study, Arteriosclerosis, Thrombosis, and Vascular Biology. (2000) 20, no. 2, 538–544, 2-s2.0-0343485089.
- 20 Tomić M., Ljubić S., and Kastelan S., The role of inflammation and endothelial dysfunction in the pathogenesis of diabetic retinopathy, Collegium Antropologicum. (2013) 37, no. supplement 1, 51–57.
- 21 Yamamoto Y., Hirose H., Saito I., Tomita M., Taniyama M., Matsubara K., Okazaki Y., Ishii T., Nishikai K., and Saruta T., Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population, Clinical Science. (2002) 103, no. 2, 137–142, 2-s2.0-0036349010.
- 22 Muni R. H., Kohly R. P., Lee E. Q., Manson J. E., Semba R. D., and Schaumberg D. A., Prospective study of inflammatory biomarkers and risk of diabetic retinopathy in the diabetes control and complications trial, JAMA Ophthalmology. (2013) 131, no. 4, 514–521, https://doi.org/10.1001/jamaophthalmol.2013.2299.
- 23 Adams A. C. and Kharitonenkov A., FGF21: the center of a transcriptional nexus in metabolic regulation, Current Diabetes Reviews. (2012) 8, no. 4, 285–293.
- 24 Stein S., Stepan H., Kratzsch J., Verlohren M., Verlohren H.-J., Drynda K., Lössner U., Blüher M., Stumvoll M., and Fasshauer M., Serum fibroblast growth factor 21 levels in gestational diabetes mellitus in relation to insulin resistance and dyslipidemia, Metabolism. (2010) 59, no. 1, 33–37, 2-s2.0-72049097133, https://doi.org/10.1016/j.metabol.2009.07.003.
- 25 Murata Y., Konishi M., and Itoh N., Fgf21 as an endocrine regulator in lipid metabolism: from molecular evolution to physiology and pathophysiology, Journal of Nutrition and Metabolism. (2011) 2011, 8, https://doi.org/10.1155/2011/981315, 981315.
- 26 Holland W. L., Adams A. C., Brozinick J. T. et al., An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice, Cell Metabolism. (2013) 17, no. 5, 790–797, https://doi.org/10.1016/j.cmet.2013.03.019.
- 27 Lin Z., Tian H., Lam K. S. et al., Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice, Cell Metabolismolism. (2013) 17, no. 5, 779–789, https://doi.org/10.1016/j.cmet.2013.04.005.
- 28 Raz I. and Gallwitz B., The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue, Review of Diabetic Studies. (2011) 8, no. 3, 288–292, 2-s2.0-84856016128, https://doi.org/10.1900/RDS.2011.8.288.
- 29 Abcouwer S. F., Angiogenic factors and cytokines in diabetic retinopathy, Journal of Clinical & Cellular Immunology. (2013) no. supplement 1, no. 11, https://doi.org/10.4172/2155-9899.
- 30 Zhou J., Wang S., and Xia X., Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy, Current Eye Research. (2012) 37, no. 5, 416–420, 2-s2.0-84859891447, https://doi.org/10.3109/02713683.2012.661114.
- 31 Simo R., Roy S., Behar-Cohen F., Keech A., Mitchell P., and Wong T. Y., Fenofibrate: a new treatment for diabetic retinopathy. Molecular mechanisms and future perspectives, Current Medicinal Chemistry. (2013) 20, no. 26, 3258–3266.
